FDG PET in Prostate Cancer.
作者信息
Jadvar Hossein
出版信息
PET Clin. 2009 Apr 1;4(2):155-61. doi: 10.1016/j.cpet.2009.05.002.
Abstract
摘要
相似文献
1
FDG PET in Prostate Cancer.
PET Clin. 2009 Apr 1;4(2):155-61. doi: 10.1016/j.cpet.2009.05.002.
2
Detection of prostate cancer by an FDG-PET cancer screening program: results from a Japanese nationwide survey.
Asia Ocean J Nucl Med Biol. 2014 Spring;2(1):19-23.
3
(11)C-methylaminoisobutyric acid (MeAIB) PET for evaluation of prostate cancer: compared with (18)F-fluorodeoxyglucose PET.
Ann Nucl Med. 2016 Oct;30(8):553-62. doi: 10.1007/s12149-016-1098-3. Epub 2016 Jun 21.
4
Diagnostic role of fluorodeoxyglucose positron emission tomography-computed tomography in prostate cancer.
Oncol Lett. 2014 Jun;7(6):2013-2018. doi: 10.3892/ol.2014.1997. Epub 2014 Mar 24.
5
Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT.
Ann Nucl Med. 2012 Feb;26(2):138-45. doi: 10.1007/s12149-011-0551-6. Epub 2011 Nov 9.
6
The Evolving Role of F-FDG PET/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer.
Front Oncol. 2021 Jul 29;11:683793. doi: 10.3389/fonc.2021.683793. eCollection 2021.
7
Clinical Relevance of Incidental Prostatic Lesions on FDG-Positron Emission Tomography/Computerized Tomography-Should Patients Receive Further Evaluation?
J Urol. 2016 Apr;195(4 Pt 1):907-12. doi: 10.1016/j.juro.2015.11.025. Epub 2015 Nov 17.
8
Does focal incidental 18F-FDG PET/CT uptake in the prostate have significance?
Abdom Imaging. 2015 Oct;40(8):3222-9. doi: 10.1007/s00261-015-0520-y.
9
Description of FDG and Prostate-Specific Membrane Antigen PET/CT Findings in Korean Patients With Advanced Metastatic Castration-Resistant Prostate Cancer.
Korean J Radiol. 2024 Nov;25(11):1022-1028. doi: 10.3348/kjr.2024.0439.
10
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Lancet Oncol. 2022 Nov;23(11):1389-1397. doi: 10.1016/S1470-2045(22)00605-2. Epub 2022 Oct 16.
引用本文的文献
1
Gene's expression underpinning the divergent predictive value of [18F]F-fluorodeoxyglucose and prostate-specific membrane antigen positron emission tomography in primary prostate cancer: a bioinformatic and experimental study.
J Transl Med. 2023 Jan 4;21(1):3. doi: 10.1186/s12967-022-03846-1.
2
Beyond the Prognostic Value of 2-[F]FDG PET/CT in Prostate Cancer: A Case Series and Literature Review Focusing on the Diagnostic Value and Impact on Patient Management.
Diagnostics (Basel). 2022 Feb 24;12(3):581. doi: 10.3390/diagnostics12030581.
3
Synthesis and Evaluation of C-Labeled Triazolones as Probes for Imaging Fatty Acid Synthase Expression by Positron Emission Tomography.
Molecules. 2022 Feb 25;27(5):1552. doi: 10.3390/molecules27051552.
4
The Emerging Role of Next-Generation Imaging in Prostate Cancer.
Curr Oncol Rep. 2022 Jan;24(1):33-42. doi: 10.1007/s11912-021-01156-1. Epub 2022 Jan 20.
5
PET Use in Cancer Diagnosis, Treatment, and Prognosis.
Methods Mol Biol. 2022;2413:23-35. doi: 10.1007/978-1-0716-1896-7_4.
6
F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy.
Can Urol Assoc J. 2021 Oct;15(10):301-307. doi: 10.5489/cuaj.7107.
7
Metastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response.
Front Oncol. 2021 Mar 4;10:627379. doi: 10.3389/fonc.2020.627379. eCollection 2020.
8
GLUT1 expression in high-risk prostate cancer: correlation with F-FDG-PET/CT and clinical outcome.
Prostate Cancer Prostatic Dis. 2020 Sep;23(3):441-448. doi: 10.1038/s41391-020-0202-x. Epub 2020 Jan 13.
9
Incidentalomas of the prostate detected by 18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.
Can Urol Assoc J. 2020 May;14(5):E180-E184. doi: 10.5489/cuaj.5976. Epub 2019 Nov 29.
10
Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with F-FDG PET/CT.
J Nucl Med. 2019 Nov;60(11):1524-1530. doi: 10.2967/jnumed.118.223263. Epub 2019 Mar 29.
本文引用的文献
1
[F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland.
Ann Nucl Med. 2008 Nov;22(9):787-93. doi: 10.1007/s12149-008-0177-5. Epub 2008 Nov 28.
2
3
Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry.
J Nucl Med. 2008 Dec;49(12):1928-35. doi: 10.2967/jnumed.108.056713. Epub 2008 Nov 7.
4
Novel tracers and their development for the imaging of metastatic prostate cancer.
J Nucl Med. 2008 Dec;49(12):2031-41. doi: 10.2967/jnumed.108.050658. Epub 2008 Nov 7.
5
Unparalleled contribution of 18F-FDG PET to medicine over 3 decades.
J Nucl Med. 2008 Oct;49(10):17N-21N, 37N.
6
Tumor cell metabolism imaging.
J Nucl Med. 2008 Jun;49 Suppl 2:43S-63S. doi: 10.2967/jnumed.107.045930.
7
Causes and consequences of increased glucose metabolism of cancers.
J Nucl Med. 2008 Jun;49 Suppl 2:24S-42S. doi: 10.2967/jnumed.107.047258.
8
Molecualr imaging of cancer: from molecules to humans. Introduction.
J Nucl Med. 2008 Jun;49 Suppl 2:1S-4S. doi: 10.2967/jnumed.108.053751.
9
Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry.
J Clin Oncol. 2008 May 1;26(13):2155-61. doi: 10.1200/JCO.2007.14.5631. Epub 2008 Mar 24.
10
Diffuse FDG uptake in acute prostatitis.
Clin Nucl Med. 2008 Apr;33(4):308-10. doi: 10.1097/RLU.0b013e3181662f8b.
Zotero 插件